QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
QQQ   282.13 (+3.14%)
AAPL   146.10 (+2.56%)
MSFT   248.88 (+3.38%)
META   140.28 (+1.20%)
GOOGL   101.64 (+3.04%)
AMZN   121.09 (+4.50%)
TSLA   249.44 (+2.90%)
NVDA   131.67 (+5.23%)
NIO   16.73 (+8.01%)
BABA   84.11 (+4.55%)
AMD   67.90 (+2.71%)
T   16.09 (+1.19%)
MU   53.96 (+4.33%)
CGC   3.14 (+7.90%)
F   12.36 (+7.76%)
GE   67.54 (+6.19%)
DIS   101.44 (+4.44%)
AMC   7.83 (+13.81%)
PYPL   92.79 (+6.43%)
PFE   44.46 (+0.72%)
NFLX   240.74 (+0.71%)
NYSE:CTLT

Catalent - CTLT Stock Forecast, Price & News

$79.79
+3.27 (+4.27%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$76.83
$80.10
50-Day Range
$72.36
$113.10
52-Week Range
$72.19
$140.55
Volume
1.83 million shs
Average Volume
1.25 million shs
Market Capitalization
$14.35 billion
P/E Ratio
28.19
Dividend Yield
N/A
Price Target
$122.13

Catalent MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
53.1% Upside
$122.13 Price Target
Short Interest
Healthy
2.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.85
Upright™ Environmental Score
News Sentiment
0.14mentions of Catalent in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$1.87 M Sold Last Quarter
Proj. Earnings Growth
16.11%
From $3.60 to $4.18 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.19 out of 5 stars

Medical Sector

5th out of 1,087 stocks

Pharmaceutical Preparations Industry

2nd out of 546 stocks

CTLT stock logo

About Catalent (NYSE:CTLT) Stock

Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics segment provides biologic cell-line; develops and manufactures cell therapy and viral based gene therapy; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, vials, and cartridges; and analytical development and testing services. The Oral and Specialty Delivery segment offers formulation, development, and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. This segment also offers oral delivery solutions platform comprising pre-clinical screening, formulation, analytical development, and current good manufacturing practices services. The Clinical Supply Services segment offers manufacturing, packaging, storage, distribution, and inventory management for drugs and biologics, and cell and gene therapies in clinical trials. The company also offers FlexDirect direct-to-patient and FastChain demand-led clinical supply services. It serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. The company was incorporated in 2007 and is headquartered in Somerset, New Jersey.

Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Stock News Headlines

Catalent (NYSE:CTLT) Sets New 1-Year Low at $72.88
Catalent is Now Oversold (CTLT) - Nasdaq
Where Catalent Stands With Analysts
Catalent Faces Several Price Target Cuts By Analysts After Q4 Results
Catalent Shares Fall 8%
Catalent, Inc. (CTLT) Q4 2022 Earnings Call Transcript
See More Headlines
Receive CTLT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Catalent and its competitors with MarketBeat's FREE daily newsletter.

CTLT Company Calendar

Last Earnings
8/29/2022
Today
10/04/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$122.13
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$105.00
Forecasted Upside/Downside
+53.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$503 million
Pretax Margin
12.53%

Debt

Sales & Book Value

Annual Sales
$4.83 billion
Cash Flow
$6.42 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
178,853,000
Market Cap
$14.35 billion
Optionable
Optionable
Beta
1.39

Key Executives

  • Mr. John R. ChiminskiMr. John R. Chiminski (Age 58)
    Exec. Chair of the Board
    Comp: $3.17M
  • Mr. Alessandro  MaselliMr. Alessandro Maselli (Age 50)
    CEO & Director
    Comp: $3.78M
  • Mr. Thomas P. CastellanoMr. Thomas P. Castellano (Age 42)
    Principal Accounting Officer, Sr. VP & CFO
    Comp: $731.92k
  • Mr. Steven L. Fasman Esq.Mr. Steven L. Fasman Esq. (Age 59)
    Exec. VP & Chief Admin. Officer
    Comp: $1.32M
  • Mr. Ricky Hopson (Age 46)
    Pres & Division Head for Clinical Devel. and Supply
  • Mr. Julien Meissonnier
    VP & Chief Scientific Officer
  • Mr. Charles Lickfold
    Sr. VP & Chief Information Officer
  • Mr. Paul Surdez
    VP of Investor Relations
  • Mr. Michael J. GrippoMr. Michael J. Grippo (Age 53)
    Sr. VP of Strategy & Corp. Devel.
  • Mr. Ricardo  PravdaMr. Ricardo Pravda (Age 50)
    Sr. VP & Chief HR Officer













CTLT Stock - Frequently Asked Questions

Should I buy or sell Catalent stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CTLT shares.
View CTLT analyst ratings
or view top-rated stocks.

What is Catalent's stock price forecast for 2022?

6 brokers have issued 12-month target prices for Catalent's stock. Their CTLT share price forecasts range from $105.00 to $145.00. On average, they expect the company's share price to reach $122.13 in the next twelve months. This suggests a possible upside of 59.6% from the stock's current price.
View analysts price targets for CTLT
or view top-rated stocks among Wall Street analysts.

How have CTLT shares performed in 2022?

Catalent's stock was trading at $128.03 at the beginning of the year. Since then, CTLT stock has decreased by 40.2% and is now trading at $76.52.
View the best growth stocks for 2022 here
.

Are investors shorting Catalent?

Catalent saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 3,650,000 shares, an increase of 11.6% from the August 31st total of 3,270,000 shares. Based on an average daily volume of 1,220,000 shares, the days-to-cover ratio is currently 3.0 days.
View Catalent's Short Interest
.

When is Catalent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our CTLT earnings forecast
.

How were Catalent's earnings last quarter?

Catalent, Inc. (NYSE:CTLT) issued its quarterly earnings data on Monday, August, 29th. The company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.15 by $0.04. The business earned $1.31 billion during the quarter, compared to analysts' expectations of $1.33 billion. Catalent had a trailing twelve-month return on equity of 14.49% and a net margin of 10.56%. The company's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.08 EPS.
Read the conference call transcript
.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2023 earnings guidance on Tuesday, September, 27th. The company provided EPS guidance of $3.65-$3.99 for the period, compared to the consensus EPS estimate of $4.15. The company issued revenue guidance of $4.97 billion-$5.22 billion, compared to the consensus revenue estimate of $5.26 billion.

What is John R. Chiminski's approval rating as Catalent's CEO?

391 employees have rated Catalent Chief Executive Officer John R. Chiminski on Glassdoor.com. John R. Chiminski has an approval rating of 80% among the company's employees.

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Abbott Laboratories (ABT), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Alibaba Group (BABA), Bristol-Myers Squibb (BMY), AT&T (T) and Cisco Systems (CSCO).

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How do I buy shares of Catalent?

Shares of CTLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $76.52.

How much money does Catalent make?

Catalent (NYSE:CTLT) has a market capitalization of $13.77 billion and generates $4.83 billion in revenue each year. The company earns $503 million in net income (profit) each year or $2.83 on an earnings per share basis.

How many employees does Catalent have?

The company employs 19,000 workers across the globe.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The official website for the company is www.catalent.com. The company can be reached via phone at (732) 537-6200, via email at investors@catalent.com, or via fax at 732-537-6480.

This page (NYSE:CTLT) was last updated on 10/4/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.